EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy

Rita C Acúrcio iD, Ron Kleiner iD, Daniella Vaskovich-Koubi iD, Bárbara Carreira iD, Yulia Liubomirski, Carolina Palma, Adva Yeheskel iD, Eilam Yeini iD, Ana S Viana, Vera Ferreira, Carlos Araújo, Michael Mor iD und 11 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202404159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Rita C Acúrcio und 22 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, 1649-003, Portugal. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2, B7-H1 Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "la Caixa" Foundation CaixaImpulse, Fundação para a Ciência e Tecnologia-Ministério da Ciência, Tecnologia e Ensino Superior FCT-MCTES.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first approved vaccines for human use against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are nanotechnology‐based. Although they are modular, rapidly produced, and can reduce disease severity, the currently available vaccines are restricted in preventing infection, stressing the global demand for novel preventive vaccine technologies. Bearing this in mind, we set out to develop a flexible nanovaccine platform for nasal administration to induce mucosal immunity, which is fundamental for optimal protection against respiratory virus infection. The next‐generation multiepitope nanovaccines co‐deliver immunogenic peptides, selected by an immunoinformatic workflow, along with adjuvants and regulators of the PD‐L1 expression. As a case study, we focused on SARS‐CoV‐2 peptides as relevant antigens to validate the approach. This platform can evoke both local and systemic cellular‐ and humoral‐specific responses against SARS‐CoV‐2. This led to the secretion of immunoglobulin A (IgA), capable of neutralizing SARS‐CoV‐2, including variants of concern, following a heterologous immunization strategy. Considering the limitations of the required cold chain distribution for current nanotechnology‐based vaccines, it is shown that the lyophilized nanovaccine is stable for long‐term at room temperature and retains its in vivo efficacy upon reconstitution. This makes it particularly relevant for developing countries and offers a modular system adaptable to future viral threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesSARS-CoV-2B7-H1 AntigenAdministration, IntranasalAnimalsMiceImmunotherapyEpitopesHumansNanoparticlesFemaleNanovaccines

Stichwörter der Autor:innen

Dendritic cellsIntranasalMHC class I and MHC class II peptidesNanovaccinesPD‐1/PD‐L1 immune checkpointsSARS‐CoV‐2siRNA

Substanzen

COVID-19 VaccinesB7-H1 AntigenEpitopesCD274 protein, humanNanovaccines

Autor:innen und Institutionen

  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, 1649-003, Portugal.
  • Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • The Blavatnik Center for Drug Discovery, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • Center of Chemistry and Biochemistry, Faculty of Sciences, University of Lisbon, Lisbon, 1749-016, Portugal.
  • Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.

ORCID-Profile: Rita C Acúrcio, Ron Kleiner, Daniella Vaskovich-Koubi, Bárbara Carreira, Adva Yeheskel, Eilam Yeini, Michael Mor, Natalia T Freund, Eran Bacharach, Ana Zarubica, Sarit Aviel-Ronen, Helena F Florindo, Ronit Satchi-Fainaro

Förderung

  • "la Caixa" Foundation CaixaImpulse
  • Fundação para a Ciência e Tecnologia-Ministério da Ciência
  • Tecnologia e Ensino Superior FCT-MCTES
  • European Research Council Proof of Concept
  • Israel Cancer Research Fund
  • 'la Caixa' Foundation
  • Israel Science Foundation
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Acúrcio, R. C., Kleiner, R., Vaskovich-Koubi, D., Carreira, B., Liubomirski, Y., Palma, C., Yeheskel, A., Yeini, E., Viana, A. S., Ferreira, V., Araújo, C., Mor, M., Freund, N. T., Bacharach, E., Gonçalves, J., Toister-Achituv, M., Fabregue, M., Matthieu, S., Guerry, C., …, & Satchi-Fainaro, R. (2024). Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202404159

Vancouver

Acúrcio RC, Kleiner R, Vaskovich-Koubi D, Carreira B, Liubomirski Y, Palma C, et al. Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy. Advanced Science. 2024. doi:10.1002/advs.202404159

BibTeX
@article{Acrcio2024,
  author = {Acúrcio, Rita C and Kleiner, Ron and Vaskovich-Koubi, Daniella and Carreira, Bárbara and Liubomirski, Yulia and Palma, Carolina and Yeheskel, Adva and Yeini, Eilam and Viana, Ana S and Ferreira, Vera and Araújo, Carlos and Mor, Michael and Freund, Natalia T and Bacharach, Eran and Gonçalves, João and Toister-Achituv, Mira and Fabregue, Manon and Matthieu, Solene and Guerry, Capucine and Zarubica, Ana and Aviel-Ronen, Sarit and Florindo, Helena F and Satchi-Fainaro, Ronit},
  title = {Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202404159}
}
Kostenlos starten →